Comparative analysis of use of triamcinolone and placebo in treatment of persistent allergic rhinitis

Abstract

The aim of the study was to determine the effect of triamcinolone monotherapy on the quality of life of patients with persistent allergic rhinitis. The study was placebo-controlled, randomized and double-blinded. The study included 46 patients in the study group and 24 patients in the control group, all were diagnosed with persistent allergic rhinitis for at least two years. Patients were examined twice after diagnosis was made. The study group was administered intramuscularly with 40 mg of triamcinolone once, while the control group was given placebo. To estimate the quality of life in both groups, a specially designed questionnaire was used, according to which the final scores were calculated. The triamcinolone group had a lower overall score on the questionnaire compared with the placebo group (p < 0.001). The difference between the scores at the beginning of the study and at the end of the first month for all indicators was statistically significant (p < 0,001). The difference in changes from the start of the study to the end of the first month (difference in treatment) between placebo and the study groups was statistically significant, in favour of the study group. Triamcinolone is a drug that improves the quality of life of patients treated for persistent allergic rhinitis, better than placebo.